Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 06, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding a specific executive transaction rather than a financial performance report.
Material Changes
The material change reported is the vesting of 2,313.93 ordinary shares under the GlaxoSmithKline Deferred Investment Award for Dr. M. M. Slaoui on August 1, 2007. Consequently, Dr. Slaoui is scheduled to receive a payment of GBP 12.61 per ordinary share on August 24, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction is noted as being in accordance with Disclosure and Transparency Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the vesting date of August 1, 2007, for Dr. M. M. Slaoui's Deferred Investment Award.
- Confirm the payment date of August 24, 2007, and the rate of GBP 12.61 per share.
- Validate the total number of vested shares as 2,313.93 ordinary shares.
- Ensure the notification was received by the company on August 3, 2007.